European Psychiatry (Jan 2021)

EPA guidance on treatment of negative symptoms in schizophrenia

  • S. Galderisi,
  • S. Kaiser,
  • I. Bitter,
  • M. Nordentoft,
  • A. Mucci,
  • M. Sabé,
  • G. M. Giordano,
  • M. Ø. Nielsen,
  • L. B. Glenthøj,
  • P. Pezzella,
  • P. Falkai,
  • S. Dollfus,
  • W. Gaebel

DOI
https://doi.org/10.1192/j.eurpsy.2021.13
Journal volume & issue
Vol. 64

Abstract

Read online

Negative symptoms of schizophrenia remain a major therapeutic challenge. The progress in the conceptualization and assessment is not yet fully reflected by treatment research. Nevertheless, there is a growing evidence base regarding the effects of biological and psychosocial interventions on negative symptoms. The importance of the distinction between primary and secondary negative symptoms for treatment selection might seem evident, but the currently available evidence remains limited. Good clinical practice is recommended for the treatment of secondary negative symptoms. Antipsychotic treatment should be optimized to avoid secondary negative symptoms due to side effects and due to positive symptoms. For most available interventions, further evidence is needed to formulate sound recommendations for primary, persistent, or predominant negative symptoms.

Keywords